In a press release, the University of Basel describes the Texas Medical Center (TMC) as the “world’s largest medical center”. Its capacities in the life sciences sector are complemented by the expertise of companies that qualify for the TMC Innovation Accelerator. This year, a total of 140 startups applied to join the international cohort of medical devices, with 16 ultimately proving successful. Artidis, a spin-off from the University of Basel, was one of the successful applicants.
Artidis, which was formed from a research group comprising the University of Basel and the Swiss Nanoscience Institute, has used its proprietary nanotechnology platform in order to develop “the first nanomechanical biomarker for cancer diagnosis and treatment optimization”. The platform integrates different types of clinical data, allowing current diagnostic processes to be shortened and personalized plans for cancer treatment to be produced. As part of the TMC, Artidis can now launch this technology on the US market. “Being part of the TMC Innovation Accelerator program is a great opportunity for us as it provides access to a unique environment at the forefront of science and innovation – the best place to take patient care to the next level”, says Marija Plodinec, CEO of Artidis, in the press release.
BaselArea.swiss has also recognized the potential of Artidis. In this regard, the startup has taken part in the location marketing organization’s Venture Mentoring program.
